MicroPort EP(SH:688351) Sou Hu Cai Jing·2025-06-23 11:55Core Viewpoint - The company, Microelectrophysiology, has shown significant growth in its financial performance, with a notable increase in net profit and revenue, while its stock valuation remains high compared to industry averages [1][3]. Financial Performance - For Q1 2025, the company reported a revenue of 1.04 billion yuan, representing a year-on-year increase of 16.77% [3]. - The net profit for the same period was 178.705 million yuan, showing a substantial year-on-year growth of 328.63% [3]. - The gross profit margin stood at 60.56% [3]. Market Position - The company's stock closed at 19.29 yuan, reflecting a rise of 4.44%, with a rolling price-to-earnings (PE) ratio of 138.02 times [1]. - In comparison, the average PE ratio for the medical device industry is 48.89 times, and the median is 35.79 times, placing Microelectrophysiology at the 110th position in the industry ranking [1]. Shareholding Structure - As of Q1 2025, a total of 15 institutions held shares in Microelectrophysiology, including 11 funds, 3 other entities, and 1 insurance company, with a total holding of 41.9337 million shares valued at 800.1 million yuan [1]. Product Portfolio - The company specializes in innovative medical devices for electrophysiological intervention and ablation therapy, focusing on integrated solutions for precise intervention navigation [2]. - Key products include the Columbus 3D cardiac electrophysiology mapping system and various types of disposable catheters and ablation devices, which have received recognition in Shanghai's 2024 biomedical product directories [2]. Awards and Recognition - The project on "High-Precision Intracardiac Intervention Navigation System" won an award at the 2024 Shanghai Youth Engineer Innovation and Entrepreneurship Competition [2].